
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is a clinical-stage biopharmaceutical company that has a promising outlook due to its focus on addressing the unmet need for TRD treatment and its strong portfolio of mebufotenin products, particularly GH001 which has shown positive results in Phase 2 trials. The completion of enrollment in Phase 1 trials for both the inhalable and intravenous formulations, as well as a successful offering that boosted the company's cash reserves, are positive indicators of its operational progress. The company's scientific visibility, with posters and presentations at major conferences, and its goal of initiating a global Phase 3 trial in late 2026, further support the positive outlook for GH Research.
Bears say
GH Research is a clinical-stage biopharmaceutical company with a narrow focus on developing treatments for depression using mebufotenin. While their portfolio includes two product candidates, GH001 and GH002, the company's near-term strategic focus remains on GH001 for the treatment of Treatment-Resistant Depression (TRD). While GH002 remains a longer-term option, the company's balance sheet has improved after a recent raise to fund further research and development. The company may face potential risks, including competition from other psychedelics and generic antidepressants, legal challenges to their patents, financial risks from ongoing net losses, and regulatory risks from FDA and DEA approval processes.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares